NPS Pharmaceuticals Reports Second Quarter Financial Results

NPS Pharmaceuticals

today reported its results for the second quarter 2010. NPS reported a net loss of $6.3 million or $0.11 per diluted share for the second quarter 2010, compared to net income of $2.6 million or $0.05 per diluted share for the second quarter 2009. The change in the company's quarterly results was driven by an increase in research and development expense in the second quarter 2010 due to the advancement of two Phase 3 registration programs. The company's cash, cash equivalents and marketable investment securities totaled $133.2 million at June 30, 2010 versus $74.9 million at December 31, 2009.